Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Fish and Richardson
Express Scripts
QuintilesIMS
Covington

Generated: July 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,688,711

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,688,711 protect, and when does it expire?

Patent 9,688,711 protects ZEMDRI and is included in one NDA.

This patent has twenty-eight patent family members in twenty-one countries.

Summary for Patent: 9,688,711
Title:Antibacterial aminoglycoside analogs
Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): ##STR00001## including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q.sub.1, Q.sub.2, Q.sub.3, R.sub.8 and R.sub.9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Inventor(s): Aggen; James Bradley (Burlingame, CA), Goldblum; Adam Aaron (Berkeley, CA), Linsell; Martin Sheringham (San Mateo, CA), Dozzo; Paola (San Francisco, CA), Moser; Heinz Ernst (San Mateo, CA), Hildebrandt; Darin James (Cupertino, CA), Gliedt; Micah James (Sunnyvale, CA)
Assignee: Achaogen, Inc. (South San Francisco, CA)
Application Number:15/001,797
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,688,711
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 9,688,711

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Achaogen Inc ZEMDRI plazomicin sulfate SOLUTION;INTRAVENOUS 210303-001 Jun 25, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,688,711

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008326297 ➤ Sign Up
Brazil PI0819319 ➤ Sign Up
Canada 2706369 ➤ Sign Up
China 101868472 ➤ Sign Up
China 103360440 ➤ Sign Up
Cyprus 1118915 ➤ Sign Up
Denmark 2217610 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Merck
Baxter
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.